"The global metastatic castrate resistant prostate cancer treatment market size was valued at USD 11.99 billion in 2024 and is expected to reach USD 22.37 billion by 2032, at a CAGR of 8.10% during the forecast period The global business landscape is undergoing a transformation, with industries increasingly leaning on deep research and actionable insights to make...